OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the Financial Times’ prestigious ‘UK Best Employers 2025’ list. This recognition ...

Partial hepatectomy did not affect serum ALT levels in animals that received lentivirus (Fig. 3). The observed liver injury may be a direct toxic effect of the viral particles or contaminants in ...

Similarly, advancements in technologies like novel in-process potency testing tools for T cell redirecting lentivirus and genomics solutions help with treatment by using lenti viral vectors for ...

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and ...

The global viral vectors for non-human primates market was valued at USD 145.8 Mn in 2023 and is projected to grow at a CAGR ...

This partnership aims to support the comprehensive development and manufacturing of lentivirus for Mongoose Bio's TCR-T pipeline, designed for cancer treatment. In October 2024, Cellipont Bioservices ...

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated ...

The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

UK companies not widely covered may potentially offer a unique opportunity to buy shares in a future market winner.